Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 29, 2009

View Archived Issues

MedImmune presents monoclonal antibodies for rheumatoid arthritis at ACR scientific meeting

A-1010002 induces long-distance post-trauma neuronal regeneration in vivo

Favorable preclinical evaluation of CM-2395 supports future phase I trial in schizophrenia

IL-2 and TNF-alpha may predict response to palliative radiopharmaceutical therapy

Ligand Pharmaceuticals acquires Metabasis Therapeutics and its pipeline of products

Bionomics completes first stage of phase I trial of BNC-210 for anxiety disorders

PharmaGap reports results from NCI's in vitro anticancer screen of GAP-107B8

Biomarker analysis shows that VT-111 reduces cardiac damage in ACS patients

Preclinical studies demonstrate potential of JNJ-1930942 for treatment of cognitive dysfunction

PD-0360324 is safe and reduces levels of bone resorption marker in healthy subjects

Cycloset induces glycemic control in type 2 diabetes patients failing thiazolidinediones

Preclinical characteristics of phase II Pfizer antipsychotic PF-00217830 described

Alkermes commences phase I ALKS-37 trial for opioid-induced constipation

GlaxoSmithKline reports results from trial of the Pandemrix H1N1 vaccine

CHMP grants marketing authorization for Regeneron's rilonacept for CAPS

Abbott Japan and Eisai submit MAA in Japan for Humira in ankylosing spondylitis

Lundbeck discloses P2X7 receptor antagonists for use as analgesics

Sterix claims 11beta-HSD1 inhibitors for treating diabetes and other conditions

Dainippon Sumitomo Pharma discovers 5-HT4 receptor agonists for GI dysfunction

E.U. approves Novartis' fully human monoclonal antibody Ilaris for CAPS

Results reported from clinical trial of Adimmune's H1N1 vaccine

Vertex reports interim results for telaprevir-based regimens in hepatitis C

AMPK activator Debio-0930 licensed to Mercury Therapeutics and Debiopharm

Nabi Biopharmaceuticals takes part in phase IIb study of NicVAX vaccine

AstraZeneca withdraws submissions from EMEA and FDA for Zactima in NSCLC

ThromboGenics and BioInvent complete recruitment into phase II trial of TB-402 in DVT

Nektar Therapeutics completes enrollment ahead of schedule in phase II NKTR-102 trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...